AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger)
13F holders, Q2 2026 (June 30)2holders +1
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger) in their 13F filings, up 1 from Q1 2026. 1 opened new positions and 0 sold out. The largest holders were Trium Capital LLP ($0) and GAMMA Investing LLC ($0).
- Company
- AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger)
- CUSIP
- G29CVR019
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 1,293,631 shares bought, net +1,293,631 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Trium Capital LLP | 0.00% | Add +100.0% | 2,585,970 | $0 |
| GAMMA Investing LLC | 0.00% | New | 646 | $0 |
"% of holder's portfolio" is AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger)'s weight in each manager's 13F, not the share of AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger) the manager owns.